

# FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden hours per response... 0.5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |  |  |  |  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 1. Name and Address of Reporting Person <sup>*</sup><br><b>Wagner Paul A.</b><br>(Last) (First) (Middle) |  |  | 2. Issuer Name and Ticker or Trading Symbol<br><b>Forte Biosciences, Inc. [ FBRX ]</b> |  |  |  |  | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)<br><b>SEE REMARKS</b> |  |  |  |  |
| <b>C/O FORTE BIOSCIENCES, INC., 3060 PEGASUS PARK DR., BLDG 6</b><br>(Street)                            |  |  | 3. Date of Earliest Transaction (MM/DD/YYYY)<br><b>1/1/2026</b>                        |  |  |  |  |  |  |  |  |  |
| <b>DALLAS, TX 75247</b><br>(City) (State) (Zip)  |  |  | 4. If Amendment, Date Original Filed (MM/DD/YYYY)                                      |  |  |  |  | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person   |  |  |  |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security<br>(Instr. 3) | 2. Trans. Date | 2A. Deemed<br>Execution<br>Date, if any | 3. Trans. Code<br>(Instr. 8) | 4. Securities Acquired (A)<br>or Disposed of (D)<br>(Instr. 3, 4 and 5) |   |                         | 5. Amount of Securities Beneficially Owned<br>Following Reported Transaction(s)<br>(Instr. 3 and 4) | 6.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr.<br>4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |
|------------------------------------|----------------|---|------------------------------|---|---|-------------------------|---|--|---|---|
|                                    |                |   |                              | Code  | V | Amount<br>(A) or<br>(D) |   |  |   |   |
| Common Stock                       | 1/1/2026       |   | M                            |   |   | 1,250                   | A   | \$0 (1)  | 83,342  | D |
| Common Stock                       | 1/1/2026       |   | F                            |   |   | 164                     | D   | \$27.27 (2)  | 83,178  | D |

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Trans.<br>Date | 3A. Deemed<br>Execution<br>Date, if any | 4. Trans.<br>Code<br>(Instr. 8) | 5. Number of<br>Derivative Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and 5) |   |       | 6. Date Exercisable<br>and Expiration Date | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form of<br>Derivative<br>Security:<br>Direct (D)<br>or Indirect<br>(I) (Instr.<br>4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |
|--|--|-------------------|---|---------------------------------|--|---|-------|--|--|---|--|--|--|---|
|  |  |                   |   |                                 | Code   | V | (A)   | (D)  |  |   |  |  |  |   |
| Restricted Stock<br>Units                        | (1)  | 1/1/2026          |   | M                               |  |   | 1,250 | (3)  | (3)  | Common<br>Stock                                     | 1,250  | \$0  | 5,000  | D |

#### Explanation of Responses:

- Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
- On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld.
- Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

#### Remarks:

CEO, Secretary and Chair of the Board

#### Reporting Owners

| Reporting Owner Name / Address | Relationships |           |         |       |
|--------------------------------|---------------|-----------|---------|-------|
|                                | Director      | 10% Owner | Officer | Other |
| Wagner Paul A.                 |               |           |         |       |

C/O FORTE BIOSCIENCES, INC.  
3060 PEGASUS PARK DR., BLDG 6  
DALLAS, TX 75247

X

SEE REMARKS

**Signatures**

/s/ Paul A. Wagner, Ph.D.

1/2/2026

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.